AG
ENTA icon

Advisor Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Advisor Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$29K – 5261
2019
Q1 		$29K Sell
300
-114
-28% -$10.2K ﹤0.01% 3749
2018
Q4 		$29K Sell
414
-198
-32% -$15.2K ﹤0.01% 3549
2018
Q3 		$52K Buy
612
+360
+143% +$36.1K ﹤0.01% 3254
2018
Q2 		$29K Buy
252
+15
+6% +$1.5K ﹤0.01% 3474
2018
Q1 		$19K Buy
+237
New +$18.2K ﹤0.01% 3706
2016
Q4 		– Sell
-840
Closed -$22K – 4534
2016
Q3 		$22K Sell
840
-188
-18% -$4.37K ﹤0.01% 3082
2016
Q2 		$22K Buy
+1,028
New +$26.9K ﹤0.01% 3015

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advisor Group's ENTA Position: Q2 2019 in Review

Advisor Group sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 300 shares — an estimated $29K sold.

Advisor Group first reported a position in ENTA in Q2 2016 and held it in 7 quarters. The position peaked at $52K in Q3 2018. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Advisor Group reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Advisor Group sold 300 Enanta Pharmaceuticals shares in Q2 2019, an estimated $29K.
  • Advisor Group first reported a position in Enanta Pharmaceuticals in Q2 2016 and held it in 7 quarters.
  • Advisor Group's Enanta Pharmaceuticals position peaked at $52K in Q3 2018.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.